Haridwar Today

Raynaud’s Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Raynaud’s Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

February 03
20:56 2023
Raynaud’s Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
DelveInsight’s, “Raynaud’s Disease- Pipeline Insight, 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Raynaud’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s Raynaud’s Disease Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Raynaud’s Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Raynaud’s Disease pipeline domain.


Key Takeaways from the Raynaud’s Disease Pipeline Report

  • Over 5+ Raynaud’s Disease pipeline therapies are in various stages of development, and their anticipated acceptance in the Raynaud’s Disease market would significantly increase market revenue. 
  • Leading Raynaud’s Disease companies developing novel drug candidates to improve the Raynaud’s Disease treatment landscape include Gesynta Pharma, United Therapeutics, and others.
  • Promising Raynaud’s Disease pipeline therapies in various stages of development include GS 248, Treprostinil, and others.


Raynaud’s Disease Overview

Raynaud’s phenomenon is a problem that causes decreased blood flow to the fingers. In some cases, it also causes less blood flow to the ears, toes, nipples, knees, or nose. This happens due to spasms of blood vessels in those areas. The spasms happen in response to cold, stress, or emotional upset. Raynaud’s can occur on its own, known as primary form. Or it may happen along with other diseases, known as secondary form. The exact cause of Raynaud’s is unknown. It is possible that some blood disorders may cause Raynaud’s by increasing the blood thickness. 

This may happen due to excess platelets or red blood cells. Or special receptors in the blood that control the narrowing of the blood vessels may be more sensitive. 

Symptoms can occur a bit differently in each person. Common symptoms include: Fingers that turn pale or white then blue when exposed to cold, or during stress or emotional upset, then red when the hands are warmed, hands that may become swollen and painful when warmed, sores on the finger pads develop, in severe cases, gangrene in the fingers that causes infection or needs amputation, this is rare. 

Raynaud’s phenomenon treatment depend on symptoms, age and general health. It also depend on how severe the condition is. There is no cure for Raynaud’s phenomenon, but it can be managed with proper treatment. The complications of Raynaud’s phenomenon is in rare cases, sores on finger pads may occur. 

These sores may progress to gangrene. In rare cases, gangrene may lead to finger amputation. For most people living with Raynaud’s, it is more of an inconvenience than a serious problem. Avoiding triggers, primarily cold, can reduce the spasms that lead to symptoms. If there is an underlying cause, such as scleroderma or lupus, it may be more difficult to manage attacks. Managing Raynaud’s includes avoiding cold, dressing warmly, and stopping smoking.


Raynaud’s Disease Pipeline Analysis: Drug Profile


Treprostinil: United Therapeutics

Treprostinil is an investigational drug being developed by United Therapeutics. Currently, the drug is in Early Phase I for the treatment of Raynaud’s phenomenon. Treprostinil, basically acts as a platelet aggregation inhibitor.


Discover more about the emerging Raynaud’s Disease drugs @ Raynaud’s Disease Treatment Drugs


Raynaud’s Disease Key Companies

  • Gesynta Pharma
  • United Therapeutics


Raynaud’s Disease Pipeline Therapies

  • GS 248
  • Treprostinil


Raynaud’s Disease Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 


Scope of the Raynaud’s Disease Pipeline Report 

  • Coverage: Global 
  • Key Raynaud’s Disease Companies: Gesynta Pharma, United Therapeutics, and others
  • Key Raynaud’s Disease Pipeline Therapies: GS 248, Treprostinil, and others


Find out more about the Raynaud’s Disease treatment options in development @ Raynaud’s Disease Clinical Trials


Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight


Other Trending Reports:

  • Asthma Diagnostic Devices Market
  • Chronic Obstructive Pulmonary Disease Treatment Devices Market
  • Airway Management Devices Market
  • Cough Assist Devices Market
  • Pulse Oximeters Market
  • Hemodialysis Catheter Devices Market


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Contact Us

Kritika Rehani

[email protected] 


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/